Irbecard 75 mg, 150 mg and 300 mg FC tablets.
PDF Leaflet Revision Date: 28 February 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of essential hypertension and diabetic nephropathy in type 2 diabetes.
Dosage (summary)
Initial dose: 150 mg once daily; may increase to 300 mg if needed.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; safety in lactation not established.
Key Drug Interactions
- Fluoroquinolones
- Potassium-sparing diuretics
- Lithium
- NSAIDs
Contraindications
- Hypersensitivity to irbesartan
- History of angioedema
- Severe renal impairment
- Bilateral renal artery stenosis
- Pregnancy
- Concomitant use with aliskiren
Common side effects
- Dizziness
- Headache
- Nausea
- Fatigue
Counselling Points
- Take once daily with or without food
- Monitor blood pressure regularly
- Report any signs of hypotension or renal issues
Serious warnings
- Risk of hypotension in volume-depleted patients
- Monitor renal function in renal impairment
Important Disclaimer
The Irbecard 75 mg, 150 mg and 300 mg FC tablets. professional information leaflet below is the property of Smart Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
